Denny Lanfear, Coherus BioSciences CEO
December 3, 2024 01:44 PM EST
Deals
Pharma

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

Nicole DeFeudis

Editor

Co­herus Bio­Sciences’ stock surged on Tues­day af­ter the com­pa­ny an­nounced plans to sell off the last biosim­i­lar in its port­fo­lio.

In­tas Phar­ma­ceu­ti­cals

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ap­plied Ther­a­peu­tics gets FDA warn­ing let­ter over study of re­ject­ed rare dis­ease drug

A service from the Financial Times